"MannKind (NASDAQ: MNKD) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $2.50 target price on the stock. Zacks’ analyst wrote, “MannKind’s fourth quarter 2012 net loss of $0.23 per share was narrower than the year-ago loss of $0.30 but wider than the Zacks Consensus Estimate of a loss of $0.18. A higher share count following the issuance of shares in Oct 2012 accounted for the lower year-over-year loss. More than financial results, we expect investor focus to remain on Afrezza. MannKind expects to present results on Afrezza in mid-August this year. The company plans to resubmit the New Drug Application (NDA) for Afrezza in late September or early October this year with a final decision for the candidate expected in Apr/Mar 2014. However, we remain concerned about the company’s over dependence on Afrezza. We see limited upside from current levels and retain our Neutral stance on the stock. “

http://www.jagsreport.com/2013/02/equities-research-analysts-ratings-reiterations-for-february-13th-adm-bdx-bto-cmcsa-csod-ddr-dis-dnb-ezch-fosl/